At last check, shares of biotech innovator and biologics contract manufacturing organization iBio Inc. (IBIO) were up 7.19% to $1.49 in after-hours trading. Thursday’s closing price for IBIO stock was $1.39, up 4.51% from the previous day’s close. IBIO stock volume on the day was reduced to 6.36 million shares from 12.29 million shares in the past 50 days. Three new antibody programs support the company’s oncology drug discovery pipeline, driving IBIO stock higher.

What program has IBIO started?

iBio is a global leader in plant-based biologic production. In iBio’s FastPharming System, automated hydroponics, and novel glycosylation technologies are combined to produce monoclonal antibodies, vaccines, bioinks, and other proteins. iBio is developing biopharmaceuticals that treat cancers, as well as fibrotic and infectious diseases. iBio CDMO LLC, a subsidiary of the Company, provides Contract Development and Manufacturing Services to the FastPharming business, as well as Glycaneering services related to recombinant protein design.

Announcing the addition of three anticancer targets to its pipeline of potential therapeutics, iBio, Inc. has taken another significant step towards harnessing the speed and throughput of its proprietary, plant-based FastPharming Protein Expression System.

• With this enhancement, IBIO expands on its new drug discovery capabilities announced just a few weeks ago.
• By partnering with best-in-class technology providers, IBIO intends to create the FastPharming System that will reduce the time and cost to move from initial concept to clinic, which will be part of its efforts to redefine the drug development paradigm.
• FairJourney Biologics SA (“FairJourney”), a leader in antibody optimization, has agreed to provide research services to IBIO.
• The deal provides IBIO with access to a proprietary antibody library and novel display technologies.
• By combining its ‘speed-to-clinic’ advantages along with Glycaneering Technologies and FairJourney’s antibody optimization technologies, IBIO may be able to rapidly develop differentiated cancer therapeutic antibodies that will be more effective against cancer cells.
• Several undisclosed IBIO collaborations are advancing rapidly towards the clinic as a result of its antibody discovery expertise in oncology.
• The glycosylation techniques IBIO uses to enhance human anti-cancer antibody development will enable IBIO to change the bioprocess paradigm.

What has IBIO accomplished?

To complement the company’s previously offered contract development and manufacturing services, IBIO is adding its own in-house drug discovery capabilities. As a result of its plant-based FastPharming System, IBIO continues to reduce the lag times and costs associated with pharmaceutical development, and at the same time, to help develop its own biopharmaceuticals to address unmet medical needs in human health and veterinary medicine.